Get the Stockscreener App
17.38
3.58%
0.60
Spyre Therapeutics Inc stock is traded at $17.38, with a volume of 805.61K.
It is up +3.58% in the last 24 hours and up +5.40% over the past month.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
See More
Previous Close:
$16.78
Open:
$17
24h Volume:
805.61K
Relative Volume:
1.53
Market Cap:
$1.05B
Revenue:
$1.23M
Net Income/Loss:
$-214.90M
P/E Ratio:
-4.2162
EPS:
-4.1222
Net Cash Flow:
$-151.25M
1W Performance:
+2.54%
1M Performance:
+5.40%
6M Performance:
-18.37%
1Y Performance:
-29.81%
1-Day Range:
$16.77
$17.80
1-Week Range:
$15.73
$17.80
52-Week Range:
$10.91
$40.26
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Name
Spyre Therapeutics Inc
Sector
Industry
Phone
(617) 651-5940
Address
221 CRESCENT STREET, WALTHAM
Compare SYRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
17.38 | 1.02B | 1.23M | -214.90M | -151.25M | -4.1222 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-25 | Initiated | Leerink Partners | Outperform |
| Mar-18-25 | Initiated | Wolfe Research | Outperform |
| Sep-04-24 | Initiated | Wedbush | Outperform |
| Jul-16-24 | Initiated | Evercore ISI | Outperform |
| May-02-24 | Initiated | Robert W. Baird | Outperform |
| Mar-01-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Dec-11-23 | Initiated | Guggenheim | Buy |
| Dec-11-23 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| Mar-21-19 | Initiated | JP Morgan | Overweight |
| Sep-04-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Apr-24-18 | Initiated | Evercore ISI | Outperform |
| Mar-14-18 | Reiterated | Needham | Buy |
View All
Spyre Therapeutics Inc Stock (SYRE) Latest News
When is the best time to exit Spyre Therapeutics Inc.Market Performance Summary & Advanced Technical Signal Analysis - Newser
Analyzing net buyer seller activity in Spyre Therapeutics Inc.July 2025 Sector Moves & Fast Entry and Exit Trade Plans - Newser
Spyre Therapeutics Inc. stock trend forecastGDP Growth & Pattern Based Trade Signal System - Newser
Is it time to cut losses on Spyre Therapeutics Inc.July 2025 Outlook & Community Supported Trade Ideas - Newser
Relative strength of Spyre Therapeutics Inc. in sector analysisJuly 2025 Institutional & Safe Investment Capital Preservation Plans - Newser
What technical models suggest about Spyre Therapeutics Inc.’s comebackWeekly Market Report & AI Enhanced Trade Execution Alerts - Newser
Long term hold vs stop loss in Spyre Therapeutics Inc.Weekly Volume Report & Verified Stock Trade Ideas - Newser
How to build a dashboard for Spyre Therapeutics Inc. stock2025 Historical Comparison & Accurate Intraday Trade Tips - Newser
Can Spyre Therapeutics Inc. recover in the next quarterWeekly Trading Summary & AI Enhanced Trading Signals - Newser
RSI + MACD Show Convergence for Spyre Therapeutics Inc.2025 Valuation Update & Consistent Income Trade Ideas - newsyoung.net
Spyre Therapeutics Inc. stock retracement – recovery analysisPortfolio Value Report & Daily Stock Momentum Reports - Newser
Will Spyre Therapeutics Inc. bounce back from current supportWeekly Gains Summary & Real-Time Volume Spike Alerts - Newser
Spyre Therapeutics Inc. stock trend outlook and recovery path2025 Earnings Impact & Technical Pattern Recognition Alerts - Newser
Using AI based signals to follow Spyre Therapeutics Inc.2025 Technical Patterns & Weekly Return Optimization Plans - Newser
Combining machine learning predictions for Spyre Therapeutics Inc.July 2025 Institutional & Technical Confirmation Alerts - Newser
Spyre Therapeutics Inc.’s volatility index tracking explainedJuly 2025 Trade Ideas & Proven Capital Preservation Methods - Newser
Will a bounce in Spyre Therapeutics Inc. offer an exitJuly 2025 Gainers & Real-Time Buy Zone Alerts - Newser
Is Spyre Therapeutics Inc. forming a bottoming basePortfolio Return Report & High Accuracy Swing Entry Alerts - Newser
How Spyre Therapeutics Inc. stock performs during market volatilityAnalyst Upgrade & Risk Adjusted Buy/Sell Alerts - Newser
What institutional flow reveals about Spyre Therapeutics Inc.Swing Trade & Weekly Top Performers Watchlists - Newser
What data driven models say about Spyre Therapeutics Inc.’s future2025 Volume Leaders & Weekly Return Optimization Alerts - Newser
Market reaction to Spyre Therapeutics Inc.’s recent newsTreasury Yields & Safe Swing Trade Setup Alerts - Newser
How hedge fund analytics apply to Spyre Therapeutics Inc. stockMarket Risk Analysis & Real-Time Volume Trigger Notifications - Newser
Can momentum traders help lift Spyre Therapeutics Inc.Quarterly Earnings Report & High Conviction Buy Zone Alerts - Newser
Published on: 2025-08-17 19:42:26 - classian.co.kr
Analyzing drawdowns of Spyre Therapeutics Inc. with statistical toolsPortfolio Risk Summary & Daily Entry Point Alerts - Newser
What’s the recovery path for long term holders of Spyre Therapeutics Inc.July 2025 Selloffs & Fast Entry and Exit Trade Plans - Newser
Traders Consider Averaging Down in Spyre Therapeutics Inc.Weekly Trend Summary & Growth Focused Investment Plans - metal.it
What moving averages say about Spyre Therapeutics Inc.July 2025 Snapshot & High Accuracy Trade Alerts - Newser
Published on: 2025-08-16 20:24:41 - Newser
Real time scanner hits for Spyre Therapeutics Inc. explainedEntry Point & AI Powered Market Entry Ideas - Newser
Why Spyre Therapeutics Inc. stock attracts strong analyst attentionPortfolio Risk Summary & Risk Controlled Daily Trade Plans - Newser
Spyre Therapeutics Inc Stock (SYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Spyre Therapeutics Inc Stock (SYRE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Albers Jeffrey W. | Director |
Oct 25 '24 |
Sale |
36.43 |
300 |
10,929 |
34,060 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):